Immunovant Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

New york, march 12, 2024 (globe newswire) -- immunovant, inc. (nasdaq: imvt), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that the united states patent and trademark office has issued u.s. patent no. 11,926,669 (“the ‘669 patent”) for imvt-1402, the company's second-generation antibody targeting the neonatal fragment crystallizable receptor (fcrn). the allowed claims cover composition of matter for the binding sequence of imvt-1402 to fcrn, method of use of the antibody for treating autoimmune disease, as well as methods for its manufacturing. not including any potential patent term extension, the ‘669 patent will expire on june 23, 2043...

New york, feb. 12, 2024 (globe newswire) -- immunovant, inc. (nasdaq: imvt), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal third quarter ended december 31, 2023.

New york, jan. 03, 2024 (globe newswire) -- immunovant, inc. (nasdaq: imvt), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that pete salzmann, m.d., chief executive officer, will provide a corporate overview at the 42nd annual j.p. morgan healthcare conference on tuesday, january 9, 2024, at 10:30 am et.

New york, dec. 20, 2023 (globe newswire) -- immunovant, inc. (nasdaq: imvt), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week phase 2 clinical trial of batoclimab in patients with graves' disease meaningfully exceeded 50% response rates.

New york, nov. 28, 2023 (globe newswire) --  immunovant, inc. (nasdaq: imvt), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced initial data from 600 mg mad cohort of a phase 1 clinical trial of imvt-1402 in healthy adults. the results show that four subcutaneously administered doses of 600 mg produced a mean igg reduction similar to high dose batoclimab, but with minimal changes in albumin and ldl-c similar to those in placebo, confirming the potential of imvt-1402 as a best-in-class neonatal fragment crystallizable receptor (fcrn) inhibitor.

Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.

Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Immunovant's IMVT-1402 shows promise for at-home autoimmune treatment, with a differentiated subcutaneous delivery. Phase 1 data indicate significant IgG reductions without major side effects, advancing toward registrational trials. Financial health appears strong with a 40-month cash runway, but increased R&D could affect this.

Some of the market's favorite biotech stocks have created immense wealth, as in the recent weight-loss drug stock boom.  On May 26, Viking Therapeutics (NASDAQ: VKTX ) was trading around $20.25.

Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival's lackluster muscle disease drug study.

Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?

The heavy selling pressure might have exhausted for Immunovant, Inc. (IMVT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.

As 2023 wrapped up, Russell 2000 stocks, mirroring the dynamics of small-to-mid-cap companies, showed resilience, outperforming their initial stance. The iShares Russell 2000 ETF (NYSEARCA: IWM ), a key barometer for these stocks, boasts over $60 billion in assets and a robust daily trading volume surpassing 40 million, setting an impressive stage for these agile market players.

The beginning of earnings season is a good time to look at stocks that analysts are upgrading. For growth-oriented investors, that may mean looking at some of the top-rated Russell 2000 stocks.